RT Journal Article SR Electronic T1 Specific heterozygous frameshift variants in hnRNPA2B1 cause early-onset oculopharyngeal muscular dystrophy JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.04.08.21254942 DO 10.1101/2021.04.08.21254942 A1 Kim, Hong Joo A1 Mohassel, Payam A1 Donkervoort, Sandra A1 Guo, Lin A1 O’Donovan, Kevin A1 Coughlin, Maura A1 Lornage, Xaviere A1 Foulds, Nicola A1 Hammans, Simon R. A1 Foley, A. Reghan A1 Fare, Charlotte M. A1 Ford, Alice F. A1 Ogasawara, Masashi A1 Sato, Aki A1 Iida, Aritoshi A1 Munot, Pinki A1 Ambegaonkar, Gautam A1 Phadke, Rahul A1 O’Donovan, Dominic G A1 Buchert, Rebecca A1 Grimmel, Mona A1 Töpf, Ana A1 Zaharieva, Irina T. A1 Brady, Lauren A1 Hu, Ying A1 Lloyd, Thomas E. A1 Klein, Andrea A1 Steinlin, Maja A1 Kuster, Alice A1 Mercier, Sandra A1 Marcorelles, Pascale A1 Péréon, Yann A1 Fleurence, Emmanuelle A1 Manzur, Adnan A1 Ennis, Sarah A1 Upstill-Goddard, Rosanna A1 Bello, Luca A1 Bertolin, Cinzia A1 Pegoraro, Elena A1 Salviati, Leonardo A1 French, Courtney E. A1 Shatillo, Andriy A1 Raymond, F Lucy A1 Haack, Tobias A1 Quijano-Roy, Susana A1 Böhm, Johann A1 Nelson, Isabelle A1 Stojkovic, Tanya A1 Evangelista, Teresinha A1 Straub, Volker A1 Romero, Norma B. A1 Laporte, Jocelyn A1 Muntoni, Francesco A1 Nishino, Ichizo A1 Tarnopolsky, Mark A. A1 Shorter, James A1 Taylor, J. Paul A1 Bönnemann, Carsten G. YR 2021 UL http://medrxiv.org/content/early/2021/04/16/2021.04.08.21254942.abstract AB RNA-binding proteins (RBPs) are essential for post-transcriptional regulation and processing of RNAs. Pathogenic missense variants in RBPs underlie a spectrum of disease phenotypes, including amyotrophic lateral sclerosis, frontotemporal dementia, inclusion body myopathy, distal myopathy, and Paget’s disease of the bone. Here, we present ten independent families with a severe, progressive, early-onset muscular dystrophy, reminiscent of oculopharyngeal muscular dystrophy (OPMD), caused by heterozygous frameshift variants in the prion-like domain of hnRNPA2B1. We found that in contrast with the previously reported missense variants, the frameshift hnRNPA2B1 variants do not promote, but rather decelerate the fibrillization of the protein. Importantly, the frameshift variants harbor altered nuclear-localization sequences and exhibit reduced affinity for the nuclear-import receptor, Karyopherin-β2, which promotes their cytoplasmic accumulation in cells and in animal models that recapitulate the human pathology. Thus, we expand the phenotypes associated with hnRNPA2B1 to include a severe, early-onset disease reminiscent of OPMD, caused by a distinct class of frameshift variants that alter its nucleocytoplasmic transport dynamics.Competing Interest StatementJ.P.T. is a consultant for 5AM and Third Rock Ventures.Funding StatementWork in C.G. B.’s laboratory is supported by intramural funds from the NIH National Institute of Neurological Disorders and Stroke. Exome sequencing was in part funded through the Clinical Center Genomics Opportunity, which is sponsored by the National Human Genome Research Institute, the NIH Deputy Director for Intramural Research, and the NIH Clinical Center. J.P.T. is supported by the Howard Hughes Medical Institute, R35NS097974, and the ALS Association (18-IIA-419). This study was supported in part by Intramural Research Grant (2-5 and 29-4 to IN; 2-5 and 30-9 to AI) for Neurological and Psychiatric Disorders of NCNP and by AMED under Grant Nos. 20ek0109490h0001 and JP19ek0109285h0003 (to IN) and Joint Usage and Joint Research Programs, the Institute of Advanced Medical Sciences, Tokushima University (2020, 2A19 to AI). The work in F.M. group was supported by the National Institute for Health Research Biomedical Research Centre at Great Ormond Street Hospital for Children NHS Foundation Trust and University College London and the MRC Centre for Neuromuscular Diseases Biobank, and by the HSS England Diagnostic and Advisory Service for Congenital Myopathies and Congenital Muscular Dystrophies in London, UK for their financial support to the DNC Muscle Pathology Service. F.M. was also funded by the European Community’s Seventh Framework Programme (FP7/2007-2013) under grant agreement n° 2012-305121 ‘Integrated European-omics research project for diagnosis and therapy in rare neuromuscular and neurodegenerative diseases (NEUROMICS)’. E.P. and L.B. are members of the European Reference Network for Neuromuscular Diseases - Project ID N° 870177 and acknowledge support from the Telethon Network of Genetic BioBank (GTB12001D) and EuroBioBank network. The work in J.L. group is supported by the France Génomique National infrastructure and by the Fondation Maladies Rares within the frame of the ‘Myocapture’ sequencing project, and by Association Française contre les Myopathies (22734). C.E.F and F.L.R. are funded by Cambridge NIHR Biomedical Research Centre and the Rosetree Foundation. L.G. was supported by an Ellison Medical Foundation/American Federation for Aging Research fellowship, Alzheimer’s Association Research fellowship, and a Target ALS Springboard Fellowship. C.M.F. was supported by NIH grants T32GM008275 and F31NS111870. A.F.F. was supported by NIH grants T32AG00255 and F31NS087676. J.S. was supported by Target ALS, Packard Foundation for ALS research, ALS Association, The G. Harold and Leila Y. Mathers Charitable Foundation, and NIH grant R01GM099836. MYOSEQ was funded by Sanofi Genzyme, Ultragenyx, LGMD2I Research Fund, Samantha J. Brazzo Foundation, LGMD2D Foundation and Kurt+Peter Foundation, Muscular Dystrophy UK, and Coalition to Cure Calpain 3. Analysis was provided by the Broad Institute of MIT and Harvard Center for Mendelian Genomics (Broad CMG) and was funded by the National Human Genome Research Institute, the National Eye Institute, and the National Heart, Lung, and Blood Institute grant UM1 HG008900, and in part by National Human Genome Research Institute grant R01 HG009141.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:For research studies, written informed consent and age-appropriate assent was obtained from all participants. Ethical approval was obtained from the NIH, National Institute of Neurological Disorders and Stroke (NINDS), Institutional Review Broad (Protocol 12-N-0095), National Center of Neurology and Psychiatry (Protocol A2019-123), University of Strasburg (Protocol DC-2012-1693), Cambridge South, UK Research Ethics Committee (approval 13/EE/0325), Health Research Authority, NRES Committee East of England - Hatfield (REC 13/EE/0398; REC 06/Q0406/33) and National Research Ethics Service (NRES) Committee North East - Newcastle & North Tyneside 1 (reference 08/H0906/28).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data generated or analysed during this study are included in this published article (and its supplementary information files).